<DOC>
	<DOCNO>NCT01049451</DOCNO>
	<brief_summary>We hypothesize corticotropin adrenocorticotrophic hormone ( ACTH ) , administer Acthar GelÂ® ( MANUFACTURER NAME ) effective control clinical disease activity pulse therapy relapsing-remitting MS add standard treatment beta-interferon . We wish determine whether ACTH , administer cluster monthly intramuscular injection ( monthly pulse therapy ) add-on beta-interferon , may safe effective alternative monthly pulse therapy MP . In addition , hypothesize pulse therapy ACTH alters immune function favor regulatory , rather pro-inflammatory T cell environment .</brief_summary>
	<brief_title>Clinical 15 Months Study Comparing Monthly Pulse ACTH ( Acthar Gel ) Therapy With Monthly Methylprednisolone ( MP , Solumedrol ) Multiple Sclerosis ( MS ) Patients Who Are Regular Beta-interferons ( Avonex , Betaseron Rebif )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>1 . Clinically definite multiple sclerosis define McDonald Criteria . 2 . Between 1865 year age . 3 . Subject must able understand sign IRB approve informed consent form prior performance studyspecific procedure willing comply require scheduling assessment protocol , include selfadministration study drug ( assign ACTH arm ) . 4 . Subjects woman childbearing potential , must negative serum pregnancy test screen visit , must willing practice reliable birthcontrol method . 5 . Subjects must least one MS relapse within last year and/or least one new T2 Gadoliniumenhanced lesion MRI stable interferon therapy . 6 . EDSS ( Expanded Disability Status Scale ) score 3.0 6.5 7 . Currently one approve betainterferon drug ( Avonex , Betaseron , Rebif ) minimum 6 month . 1 . Women either pregnant breastfeeding , woman childbearing potential ( define surgically sterile least two year post menopausal ) use one follow birth control method : tubal ligation , implantable contraception device , oral , patch , injectable transdermal contraceptive , barrier method sexual activity restrict vasectomized partner . 2 . Uncontrolled hypertension , clinically significant cardiac arrhythmia , gastrointestinal ulcer , uncontrolled diabetes mellitus , osteoporosis , stage renal failure , psychiatric disorder clinically significant general health condition may interfere trial participation . 3 . Subject history drug alcohol abuse within past year . 4 . Subject corticosteroid treatment within last 90 day . 5 . Subject start new medication within last 30 day . 6 . Subject Tysabri treatment presently within 6 month screen . 7 . Subject Novantrone , Cellcept , Rituxan chemotherapeutic treatment presently within 6 month screen . 8 . Subject participant another research project . 9 . Subject contraindication either ACTH MP administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>ACTH</keyword>
	<keyword>Steroids</keyword>
</DOC>